Chronos' Deal With Shire Is 'Just The Start' Of Its Acquisitive New Strategy
Chronos Therapeutics' acquisition of three preclinical central nervous system (CNS) disease-targeting assets from Shire PLC is the first of a possible series of deals the emerging biotech is seeking under its new business strategy.
You may also be interested in...
Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.